{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.6","value":"112.6"},{"groupId":"OG001","spread":"11.1","value":"197.6"},{"groupId":"OG002","spread":"26.3","value":"626.5"},{"groupId":"OG003","spread":"22.1","value":"932.0"},{"groupId":"OG004","spread":"23.4","value":"2064.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"22"}],"units":"Participants"}],"description":"Area under the observed concentration-time curve from the time of dosing to Day 7 calculated by log-linear trapezoidal approximation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received SEA-BCMA 100 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part A: SEA-BCMA 100mg"},{"description":"Participants received SEA-BCMA 200 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG001","title":"Part A: SEA-BCMA 200mg"},{"description":"Participants received SEA-BCMA 400 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG002","title":"Part A: SEA-BCMA 400mg"},{"description":"Participants received SEA-BCMA 800 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG003","title":"Part A: SEA-BCMA 800mg"},{"description":"Participants received SEA-BCMA 1600 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG004","title":"Part A: SEA-BCMA 1600mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Pre dose, 1 and 2 hour intradose, end of drug administration, 2, 6 , 24, 72, and 168 hours post end of infusion on Day 1","title":"Area Under the Serum Concentration-Time Curve From Time 0 to Day 7 (AUC0-7) of SEA-BCMA: Part A","type":"SECONDARY","unitOfMeasure":"Day*ug/mL"}